Form 4: PTC Therapeutics Executive Sells Shares Under 10b5-1 Plan

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, Inc., reported transactions involving the sale of common stock under a pre-arranged trading plan.

Summary

• Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, Inc., executed a series of transactions on July 6, 2026.
• These transactions involved the sale of common stock under a Rule 10b5-1 trading plan adopted on September 10, 2025.
• Several sales occurred at weighted average prices ranging from $82.76 to $86.73 per share.
• The filing also notes the acquisition of stock options and the reporting person's beneficial ownership of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions under a pre-established plan, without indicating significant positive or negative corporate developments.

Negatives

• Executive Mark Elliott Boulding sold a significant number of shares, totaling thousands across multiple transactions.
• The sales occurred at various weighted average prices, indicating a divestment strategy.
• The total number of shares beneficially owned decreased following these reported transactions.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by executives is common practice to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders may note the executive's stock sales, but the use of a 10b5-1 plan suggests these are pre-planned and not necessarily indicative of negative sentiment towards the company's future prospects.

Key Dates

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Executive Compensation, Beneficial Ownership